CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05098132
Title field or adapter rule: {'original_value': 'A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-11-01T01:03:03.691913+00:00
Published At: 2026-10-29T00:00:00+00:00
Record Updated At: 2026-10-29
Source Retrieved At: 2026-11-01T01:03:02.902675+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Untreated Advanced NSCLC", "1st Line NSCLC"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-29", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05098132"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Phase 1a: STK-012 + pembrolizumab dose escalation', 'Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1a: STK-012 monotherapy dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 1b: STK-012 + pembrolizumab dose expansion', 'Phase 1b: STK-012 monotherapy expansion', 'Phase 2: Arm A', 'Phase 2: Arm B'], 'description': 'Engineered Interleukin-2 (IL-2) selective for antigen activated T cells', 'name': 'STK-012', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Phase 1a: STK-012 + pembrolizumab dose escalation', 'Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 1b: STK-012 + pembrolizumab dose expansion', 'Phase 2: Arm A', 'Phase 2: Arm B', 'Phase 2: Arm C'], 'description': 'anti-PD-1 monoclonal antibody', 'name': 'pembrolizumab KEYTRUDA®', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 2: Arm A', 'Phase 2: Arm B', 'Phase 2: Arm C'], 'description': 'chemotherapy', 'name': 'pemetrexed', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Phase 1a: STK-012 + standard of care (SoC) dose escalation', 'Phase 1b: STK-012 + SoC dose expansion', 'Phase 2: Arm A', 'Phase 2: Arm B', 'Phase 2: Arm C'], 'description': 'chemotherapy', 'name': 'carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.